Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1344 ARTÍCULOS , VIENDO DEL 16 AL 30

Review: unchained maladie - a reassessment of the role of Ubb(+1) -capped polyubiquitin chains in Alzheimer's disease

Chadwick L, Gentle L, Strachan J, Layfield R.

Neuropathol Appl Neurobiol. 2012 Apr;38(2):118-31. doi: 10.1111/j.1365-2990.2011.01236.x.

3D texture analysis on MRI images of Alzheimer's disease

Zhang J, Yu C, Jiang G, Liu W, Tong L.

Brain Imaging Behav. 2012 Mar;6(1):61-9. doi: 10.1007/s11682-011-9142-3.

Alzheimer's disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms

von Bernhardi R, Eugenín J.

Antioxid Redox Signal. 2012 May 1;16(9):974-1031. doi: 10.1089/ars.2011.4082. Epub 2012 Feb 7.

Amyloid precursor proteins, neural differentiation of pluripotent stem cells and its relevance to Alzheimer's disease

Khandekar N, Lie KH, Sachdev PS, Sidhu KS.

Stem Cells Dev. 2012 May 1;21(7):997-1006. doi: 10.1089/scd.2011.0564. Epub 2012 Jan 18.

Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease

Uenaka K, Nakano M, Willis BA, Friedrich S, Ferguson-Sells L, Dean RA, Ieiri I, Siemers ER.

Clin Neuropharmacol. 2012 Jan-Feb;35(1):25-9. doi: 10.1097/WNF.0b013e31823a13d3.

The prion protein unstructured N-terminal region is a broad-spectrum molecular sensor with diverse and contrasting potential functions

Béland M, Roucou X.

J Neurochem. 2012 Mar;120(6):853-68. doi: 10.1111/j.1471-4159.2011.07613.x.

Nuclear and mitochondrial DNA oxidation in Alzheimer's disease

Santos RX, Correia SC, Zhu X, Lee HG, Petersen RB, Nunomura A, Smith MA, Perry G, Moreira PI.

Free Radic Res. 2012 Apr;46(4):565-76. doi: 10.3109/10715762.2011.648188. Epub 2012 Jan 23.

Butyrylcholinesterase is associated with β-amyloid plaques in the transgenic APPSWE/PSEN1dE9 mouse model of Alzheimer disease

Darvesh S, Cash MK, Reid GA, Martin E, Mitnitski A, Geula C.

J Neuropathol Exp Neurol. 2012 Jan;71(1):2-14. doi: 10.1097/NEN.0b013e31823cc7a6.

Β-site APP-cleaving enzyme 1 trafficking and Alzheimer's disease pathogenesis

Tan J, Evin G.

J Neurochem. 2012 Mar;120(6):869-80. doi: 10.1111/j.1471-4159.2011.07623.x. Epub 2012 Jan 23.

Reviewing the role of donepezil in the treatment of Alzheimer's disease

Doody RS, Cummings JL, Farlow MR.

Curr Alzheimer Res. 2012 Sep;9(7):773-81. doi: 10.2174/156720512802455412.

Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in Alzheimer's disease

Tobinick E.

Curr Alzheimer Res. 2012 Jan;9(1):99-109. doi: 10.2174/156720512799015073.

Health state values for use in the economic evaluation of treatments for Alzheimer's disease

Shearer J, Green C, Ritchie CW, Zajicek JP.

Drugs Aging. 2012 Jan 1;29(1):31-43. doi: 10.2165/11597380-000000000-00000.

Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease

de la Monte SM.

Drugs. 2012 Jan 1;72(1):49-66. doi: 10.2165/11597760-000000000-00000.

Metals in Alzheimer's disease: a systemic perspective

Squitti R.

Front Biosci (Landmark Ed). 2012 Jan 1;17(2):451-72. doi: 10.2741/3938.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias